CIMERLI®
(ranibizumab-eqrn) injection

Discover CIMERLI®

An FDA-approved treatment for five retinal conditions[1]

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

- Wet age-related macular degeneration (wAMD)
- Diabetic retinopathy and diabetic macular edema (DR and DME)
- Myopic choroidal neovascularization (mCNV)
- Macular edema following retinal vein occlusion (RVO)

CIMERLI® (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection).

Please click for Full Prescribing Information and see Important Safety Information throughout.

Understanding your eye condition

If you've been diagnosed with

- Wet age-related macular degeneration (wAMD)
- Diabetic retinopathy and/or diabetic macular edema (DR, DME)
- Myopic choroidal neovascularization (mCNV)
- Macular edema following retinal vein occlusion (RVO)

you may be experiencing issues with your vision.



Healthy eye

IMPORTANT SAFETY INFORMATION

What important safety information should I know about CIMERLI® (ranibizumab-eqrn)?

- You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away

Please click for Full Prescribing Information and see Important Safety Information throughout.

In these conditions, problems with eyesight can occur when:

- Abnormal blood vessels grow in a part of the eye known as the retina
- Or, when these blood vessels leak fluid into an area of the retina called the macula



One of the contributing factors that leads to the overgrowth of these blood vessels is the presence of a protein called vascular endothelial growth factor (VEGF). Medicine to help treat these conditions, called anti-VEGF treatment, works by blocking the VEGF protein. **CIMERLI® (ranibizumab-eqrn) is an anti-VEGF treatment that slows the growth of abnormal blood vessels in the eye.**[1]

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection

Please click for Full Prescribing Information and see Important Safety Information throughout.

What is **CIMERLI®?**

CIMERLI®
(ranibizumab-eqrn) injection

CIMERLI® is an FDA-approved biosimilar that is interchangeable with Lucentis® (ranibizumab injection)[1]

CIMERLI® is a biosimilar—a type of biologic medicine that is highly similar to the FDA-approved biologic Lucentis®.[2]

CIMERLI® can be used to treat **the same eye conditions as Lucentis®**, and as an interchangeable biosimilar it is expected to have **the same effectiveness and safety**, which makes it possible to be directly substituted for Lucentis®.[1,2]

With no clinically meaningful differences between the two medicines, your doctor can choose to start or transition you to CIMERLI® without impacting your treatment.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients

Please click for Full Prescribing Information and see Important Safety Information throughout.

Why are biosimilars important?[3,4]

Biosimilars were established to

- Help reduce out-of-pocket & medication costs for patients
- Make important treatments accessible to patients who need them
- Potentially help reduce healthcare spending

all while maintaining the same quality, safety, and effectiveness of treatment.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI® (ranibizumab-eqrn)?

- Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye and detached retinas. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea, and cough

Please click for Full Prescribing Information and see Important Safety Information throughout.

What you can expect from CIMERLI®[1,2]

CIMERLI® (ranibizumab-eqrn) injection

Your doctor has chosen to start or transition you to CIMERLI®.

Here are some things you may find helpful to know:

- **The same treatment approach:** Both treatments are given as injections to the eye and are dosed the same way. Treatment is typically recommended monthly, but your doctor will determine a dosing schedule that is appropriate for you.
- **The same way of working:** Both treatments work the same way in the eye and are expected to produce the same clinical results.
- **The same effectiveness and safety:** CIMERLI® can be substituted for Lucentis® without compromising treatment impact or safety. CIMERLI® was carefully reviewed and thoroughly evaluated by a rigorous FDA-approval process, and it is required to meet high FDA standards for consistent manufacturing to ensure medication quality and safety.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products

Please click for Full Prescribing Information and see Important Safety Information throughout.

Coherus Solutions™

Financial support is available

CIMERLI Solutions™, part of the Coherus Solutions™ family of support services, offers a range of financial assistance programs for patients who are prescribed CIMERLI® (ranibizumab-eqrn).

Please see following pages for more information.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- CIMERLI® is for prescription use only

Please click for Full Prescribing Information and see Important Safety Information throughout.

Financial support is available

Co-Pay Savings Program

The Co-Pay Savings Program may cover out-of-pocket expenses associated with CIMERLI® (ranibizumab-eqrn) and the injection procedure for eligible patients with commercial insurance†:

Please see the financial support eligibility criteria on page 10.

As little as **$0** **per dose of CIMERLI®** with a maximum annual benefit of $15,000 for drug costs per calendar year‡

As little as **$0** **per injection of CIMERLI®** with a maximum annual benefit of $1,000 for injection costs per calendar year‡

IMPORTANT SAFETY INFORMATION

What important safety information should I know about CIMERLI®?

- You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away

Please click for Full Prescribing Information and see Important Safety Information throughout.

Financial support is available

Patient Assistance Program

CIMERLI® (ranibizumab-eqrn) may be available to you at no cost if you are uninsured, functionally underinsured, or are a Medicare patient experiencing financial hardship.§

Independent Foundation Support

CIMERLI Solutions™ may be able to help you find financial support through charitable foundations, or you can choose to contact these independent assistance foundations directly.¶

Please see the financial support eligibility criteria on page 10.

Ask your doctor's office to help you apply to CIMERLI® financial support programs

To learn more, visit CIMERLI.com/patients or contact 1-844-483-3692.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection

Please click for Full Prescribing Information and see Important Safety Information throughout.

Financial support eligibility criteria

†Patient Drug and Injection Co-Pay Eligibility Criteria:

- Be prescribed CIMERLI® for a medically appropriate purpose consistent with its FDA-approved labeling within 180 days of program enrollment
- Have commercial (private or non-governmental) health insurance that covers the medication costs of CIMERLI®
- Over the age of 18 years old and a US resident
- For Administration: Not a resident or get treatments in Minnesota, Rhode Island
  - If a resident of Massachusetts, injection administration may only be paid directly to the patient. Additional information may be required
- Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
- Not seek reimbursement from any third party, including payers, charitable foundations, or flexible spending account (FSAs) or healthcare savings accounts (HSAs) for all or any part of the benefit received by Coherus through this program
- Other restrictions apply, see Terms & Conditions at CIMERLI.com
- It is not valid for cash-paying patients or where prohibited by law
- Co-pay Savings Program subject to change or discontinuation without notice. This is not health insurance

‡Coherus's Co-Pay Savings Program covers the cost of medication and injection and does not cover costs associated with the office visit.

§Patient Assistance Eligibility Criteria:

Patients must be either: (a) uninsured; (b) functionally underinsured‖; or (c) traditional Medicare FFS insured patient(s) that demonstrate financial hardship and cannot afford their cost-sharing obligation as evidenced by a signed attestation from their provider.

Additionally, patients must

- Have an adjusted annual household income of ≤500% of Federal Poverty Level (FPL)
- Complete and sign consent form and, when applicable, provide income documentation
- Be under the care of a US licensed provider, and receive CIMERLI® in an established practice located in the US incident to the prescribing physician's professional services in the outpatient setting
- Be a US resident of any US state
- Have diagnosis and dosing that are consistent with FDA-approved indication for CIMERLI®
- Not have any other financial support options

‖Functionally Underinsured means the patient does not have coverage for CIMERLI® or any other ranibizumab product (biosimilar or reference).

¶Eligibility requirements, type of assistance, and application process varies.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients

*An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Patients taking CIMERLI® can expect similar clinical results and side effects as the reference product, Lucentis®. Interchangeability of CIMERLI® has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

You may report side effects to Coherus BioSciences at 1-800-483-3692 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click for Full Prescribing Information and see Important Safety Information throughout.

References: 1. CIMERLI® (ranibizumab-eqrn) prescribing information. Redwood City, CA: Coherus BioSciences, Inc. **2.** Biosimilar and Interchangeable Products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products#biological. Published October 23, 2017. Accessed on May 19, 2022. **3.** The U.S. Generic & Biosimilar Medicines Savings Report. Accessiblemeds.org. https://accessiblemeds.org/sites/default/files/2021-10/AAM-2021-US-Generic-Biosimilar-Medicines-Savings-Report-web.pdf. Published 2021. Accessed on February 22, 2022. **4.** Makurvet F. Biologics vs. small molecules: Drug costs and patient access. *Med Drug Discov*. 2021;9:100075. doi:10.1016/j.medidd.2020.100075.

CIMERLI®
(ranibizumab-eqrn) injection

CIMERLI® is given as an injection in the eye to **treat certain retinal conditions**[1]:

- Wet age-related macular degeneration (wAMD)
- Diabetic retinopathy and/or diabetic macular edema (DR, DME)
- Myopic choroidal neovascularization (mCNV)
- Macular edema following retinal vein occlusion (RVO)

IMPORTANT SAFETY INFORMATION (CONTINUED)

What important safety information should I know about CIMERLI®?

- Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection

For additional Safety Information, please talk to your doctor and click for the CIMERLI® Full Prescribing Information.

Financial support is available with **CIMERLI Solutions™**

To learn more, visit **CIMERLI.com/patients** or contact 1-844-483-3692.

CIMERLI®
(ranibizumab-eqrn) injection

0622-CIM-P041r1